Updated Jul 16, 2026
Chacko Jacob has filed 1 SEC Form 4 filing across 1 company in the last 90 days — selling. Lifetime open-market sales: $3.07M.
Jacob Chacko is the President and CEO of Oric Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on developing therapies for cancer. He has been involved with the company through various SEC filings, indicating his active role in leadership.
| Role | Insider |
|---|---|
| Notability | 30/100 |
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2025-10-06 | ORIC | Oric Pharmaceuticals, Inc. | S — Open-market sale | 37.5K | $12.32 | $462K |
| 2025-09-30 | ORIC | Oric Pharmaceuticals, Inc. | S — Open-market sale | 53.0K | $12.05 | $639K |
| 2025-09-30 | ORIC | Oric Pharmaceuticals, Inc. | S — Open-market sale | 34.5K | $12.01 | $415K |
| 2025-09-22 | ORIC | Oric Pharmaceuticals, Inc. | S — Open-market sale | 125.0K | $10.80 | $1.35M |
| 2024-12-17 | ORIC | Oric Pharmaceuticals, Inc. | S — Open-market sale | 24.7K | $8.28 | $204K |
| 2024-12-17 | ORIC | Oric Pharmaceuticals, Inc. | M — Option exercise | 67.0K | $0.00 |
Jacob Chacko is the President and CEO of Oric Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on developing therapies for cancer. He has been involved with the company through various SEC filings, indicating his active role in leadership.…
1 primary Form 4 filings in the last 90 days, covering 1 company.
Recorded transactions: 0 open-market purchases () and 5 open-market sales ($3.07M) across all tracked filings.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live Chacko Jacob profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.